Home Crystal structure of methyl (E)-4-((4-methylphenyl)sulfonamido)but-2-enoate, C12H15NO4S
Article Open Access

Crystal structure of methyl (E)-4-((4-methylphenyl)sulfonamido)but-2-enoate, C12H15NO4S

  • Shanshan Weng ORCID logo EMAIL logo
Published/Copyright: April 18, 2025

Abstract

C12H15NO4S, monoclinic, P21/c (no. 14), a = 16.4941(3) Å, b = 6.95290(10) Å, c = 11.8288(2) Å, β = 106.986(2)°, V = 1297.37(4) Å3, Z = 4, Rgt(F) = 0.0440, wRref(F2) = 0.1226, T = 220(1) K.

CCDC no.: 2424758

The molecular structure is shown in the figure. Table 1 contains the crystallographic data. The list of the atoms including atomic coordinates and displacement parameters can be found in the cif- file attached to this article.

Table 1:

Data collection and handling.

Crystal: Clear pale colourless block
Size: 0.13 × 0.12 × 0.10 mm
Wavelength: Cu Kα radiation (1.54184 Å)
μ: 2.30 mm−1
Diffractometer, scan mode: Oxford Diffraction, ω scans
θmax, completeness: 71.8°, 100 %
N(hkl)measured, N(hkl)unique, Rint: 5222, 2489, 0.015
Criterion for Iobs, N(hkl)gt: Iobs > 2 σ(Iobs), 2,401
N(param)refined: 170
Programs: Oxford, 1 Olex2, 2 SHELX 3 , 4

1 Source of materials

To the mixture of 4-methylbenzenesulfonamide (0.3 mmol) and K2CO3 (0.3 mmol), the methyl (E)-4-bromobut-2-enoate (0.3 mmol) was successively added into the tube. The reaction mixture was stirred at room temperature under air for 3 h. The resulting mixture was quenched with saturated NH4Cl solution (10 mL), and the mixture was extracted with AcOEt (3 × 25 mL). The organic layers were dried over MgSO4 and concentrated at reduced pressure. The residue was purified by column chromatography on silica gel providing the title compound. The colorless crystals of the title compound were obtained by slow evaporation of a CH3Cl solution at room temperature.

2 Experimental details

Position of the H atoms were calculated based on geometric criteria (C–H = 0.97 and 0.93 for methyl and aromatic atoms, respectively) than have been placed in their calculated position and refined isotropically using a riding model with Uiso(H) = 1.5 Ueq for methyl and Uiso(H) = 1.2 for all others.

3 Comment

Methyl crotonate is a valuable α,β-unsaturated ester widely utilized in organic synthesis and industrial applications. 4 , 5 Its conjugated double bond and ester functionality make it a versatile intermediate for polymerization, catalysis, and fine chemical production. Sulfonamide represents privileged structural motif that plays a pivotal role in modern drug discovery and development, prominently featured in natural product architectures, therapeutic agents, and bioactive compounds. 6 , 7 , 8 , 9 , 10 The integration of methyl crotonate and sulfonamide moieties in hybrid compounds is anticipated to demonstrate significant biological activity, attributed to the complementary interactions of their functional groups.

The solid structure of the title complex is depicted in the figure. One carbon-oxygen double bond exists in the compound, the C–O double bond distance (C10–O3) is 1.207(2) Å. The angle of C10–O4–C11 is 116.04(14)°. The bond distances of S–O are 1.4293(13) Å (S1–O1) and 1.4324(12) Å (S1–O2). The other bond distances and angles are in their normal ranges according to the previously reported compounds. 11


Corresponding author: Shanshan Weng, Department of Hematology, The Dingli Clinical College of Wenzhou Medical University (The Second Affiliated Hospital of Shanghai University, Wenzhou Central Hospital), Zhejiang, 325000, China, E-mail:

Acknowledgments

This project was supported by Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (Grant No. 2025KY1505 and Grant No. 2021KY1078).

References

1. Oxford Diffraction Ltd. CrysAlisPRO: Abingdon, Oxfordshire, England, 2006.Search in Google Scholar

2. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H. OLEX2: A Complete Structure Solution, Refinement and Analysis Program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Search in Google Scholar

3. Sheldrick, G. M. Crystal Structure Refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Search in Google Scholar

4. Oyeyemi, V. B.; Keith, J. A.; Carter, E. A. Eliminating Systematic Errors in DFT via Connectivity–Based Hierarchy: Accurate Bond Dissociation Energies of Biodiesel Methyl Esters. J. Phys. Chem. A 2014, 118, 7392–7403; https://doi.org/10.1021/jp412727w.Search in Google Scholar PubMed

5. Gaïl, S.; Sarathy, S. M.; Thomson, M. J.; Diévart, P.; Dagaut, P. Experimental and Chemical Kinetic Modeling Study of Small Methyl Esters Oxidation: Methyl (E)-2-butenoate and Methyl Butanoate. Combust. Flame 2008, 155, 635–650; https://doi.org/10.1016/j.combustflame.2008.04.007.Search in Google Scholar

6. Banerjee, M.; Poddar, A.; Mitra, G.; Surolia, A.; Owa, T.; Bhattacharyya, B. Sulfonamide Drugs Binding to the Colchicine Site of Tubulin: Thermodynamic Analysis of the Drug-Tubulin Interactions by Isothermal Titration Calorimetry. J. Med. Chem. 2005, 48, 547–555; https://doi.org/10.1021/jm0494974.Search in Google Scholar PubMed

7. Scozzafava, A.; Owa, T.; Mastrolorenzo, A.; Supuran, C. T. Anticancer and Antiviral Sulfonamides. Curr. Med. Chem. 2003, 10, 925–953; https://doi.org/10.2174/0929867033457647.Search in Google Scholar PubMed

8. Bano, S.; Javed, K.; Ahmad, S.; Rathish, I. G.; Singh, S.; Alam, M. S. Synthesis and Biological Evaluation of Some New 2-pyrazolines Bearing Benzene Sulfonamide Moiety as Potential Anti-inflammatory and Anti-cancer Agents. Eur. J. Med. Chem. 2011, 46, 5763–5768; https://doi.org/10.1016/j.ejmech.2011.08.015.Search in Google Scholar PubMed

9. Apaydin, S.; Török, M. Sulfonamide Derivatives as Multi-Target Agents for Complex Diseases. Bioorg. Med. Chem. Lett. 2019, 29, 2042–2050; https://doi.org/10.1016/j.bmcl.2019.06.041.Search in Google Scholar PubMed

10. Yoshino, H.; Ueda, N.; Niijima, J.; Sugumi, H.; Kotake, Y.; Koyanagi, N.; Yoshimatsu, K.; Asada, M.; Watanabe, T.; Nagasu, T.; Tsukahara, K.; Kitoh, K. Novel Sulfonamides as Potential, Systemically Active Antitumor Agents. J. Med. Chem. 1992, 35, 2496–2497; https://doi.org/10.1021/jm00091a018.Search in Google Scholar PubMed

11. Lishchynskyi, A.; Muñiz, K. An Approach to the Regioselective Diamination of Conjugated Di- and Trienes. Chem. Eur. J. 2012, 18, 2212–2216; https://doi.org/10.1002/chem.201103435.Search in Google Scholar PubMed

Received: 2025-02-24
Accepted: 2025-04-01
Published Online: 2025-04-18
Published in Print: 2025-06-26

© 2025 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of 5,5′-bis(2,4,6-trinitrophenyl)-2,2′-bi(1,3,4-oxadiazole), C16H4N10O14
  4. Crystal structure of catena-poly[(μ3-4,4′-oxydibenzoato- κ5 O,O: O,O:O)-bis(2,4,6-tri(3-pyridine)-1,3,5-triazine-κ1 N)cadmium(II)], C50H32CdN12O5
  5. The crystal structure of 1,4-diazepane-1,4-diium potassium trinitrate, C5H14KN5O9
  6. The crystal structure of benzyl 2,2,5,5-tetramethylthiazolidine-4-carboxylate, C15H21NO2S
  7. Crystal structure of 2-hydroxyethyl-triphenylphosphonium tetracyanidoborate, C24H20BN4OP
  8. The crystal structure of 1-methyl-3-(N-methylnitrous amide–N-methylene) imidazolidine-2,4,5-trione
  9. Crystal structure of N-((3-cyano-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-4-(2,2,2-trifluoroacetyl)-1H-pyrazol-5-yl)carbamoyl)-2,6-difluorobenzamide, C20H7Cl2F8N5O3S
  10. Crystal structure of 5-(2,2-difluoropropyl)-5-methylbenzo[4,5]imidazo[2,1-a] isoquinolin-6(5H)-one, C20H18F2N2O
  11. The crystal structure of N′,N″-[1,2-bis(4-chlorophenyl)ethane-1,2-diylidene]bis(furan-2- carbohydrazide), C24H16Cl2N4O4
  12. Crystal structure of [(4-bromobenzyl)triphenylphosphonium] tetrabromoantimony(III), [C25H21BrP]+[SbBr4]
  13. Crystal structure of [(4-bromobenzyl)triphenylphosphonium] tetrabromidoindium(III), [C25H21BrP]+[InBr4]
  14. The crystal structure of 4-carboxy-2-oxobutan-1-aminium chloride, C5H10ClNO3
  15. Crystal structure of (4-(4-chlorophenyl)-1H-pyrrole-3-carbonyl)ferrocene, C21H16ClFeNO
  16. The crystal structure of dichlorido(η6-p-cymene)(triphenylarsine)ruthenium(II), C28H29AsCl2Ru
  17. Crystal structure of (Z)-2-hydroxy-N′-(1-(o-tolyl)ethylidene)benzohydrazide, C16H16N2O2
  18. The crystal structure of 10-(1-bromoethyl)-14-(bromomethyl)dibenzo[a, c]acridine, C24H17NBr2
  19. Synthesis and crystal structure of 6-methoxy-7-[(4-methoxyphenyl)methoxy]-2H-1-benzopyran-2-one, C18H16O5
  20. Synthesis and crystal structure of ethyl 4-((4-trifluoromethylbenzyl)amino)benzo, C17H16F3NO2
  21. The crystal structure of (Z)-2-(tert-butyl)-6-(7-(tert-butyl)-5-methylbenzo[d][1,3]oxathiol-2-ylidene)-4-methylcyclohexa-2,4-dien-1-one, C23H28O2S
  22. The crystal structure of (R)-2-aminobutanamide hydrochloride, C4H11ClN2O
  23. Crystal structure of bromido[hydridotris(3-tert-butyl-5-isopropylpyrazolyl)borato-κ3 N,N′,N″]copper(II), C30H52BBrCuN6
  24. Crystal structure of chlorido{hydridotris[3-mesityl-5-methyl-1H-pyrazol-1-yl-κN3]borato}-copper(II) dichloromethane monosolvate
  25. Crystal structure of 4-[3,5-bis(propan-2-yl)-1H-pyrazol-4-yl]pyridine, C14H19N3
  26. Crystal structure of ((4-(4-bromophenyl)-1H-pyrrol-3-yl)methyl)ferrocene, C21H16BrFeNO
  27. Crystal structure of [(4-chlorobenzyl)triphenylphosphonium] dichloridocopper(I), {[C25H21ClP]+[CuCl2]}n
  28. The crystal structure of {Cu(2,9-diisopropyl-4,7-diphenyl-1,10-phenanthroline)[4,5-bis(diphenylphosphino)-9,9-dimethylxanthene]}+ PF6·1.5(EtOAC)
  29. Crystal structure of 3,5-bis(t-butyl)-1H-pyrazol-4-amine, C11H21N3
  30. Crystal structure of [(2,4-dichlorobenzyl)triphenylphosphonium] trichloridocopper(II), [C25H20Cl2P]+[CuCl3]
  31. The crystal structure of dipotassium sulfide, K2S
  32. Crystal structure of (4-(4-methoxyphenyl)-1H-pyrrole-3-carbonyl)ferrocene, C22H19FeNO2
  33. Crystal structure of (E)-6-(4-methylpiperazin-1-yl)-2-(4-(trifluoromethyl)benzylidene)-3, 4-dihydronaphthalen-1(2H)-one, C23H23F3N2O
  34. Crystal structure of (E)-6-morpholino-2-(4-(trifluoromethyl)benzylidene)-3,4-dihydronaphthalen-1(2H)-one, C22H20F3NO2
  35. Crystal structure of Ce9Ir37Ge25
  36. The crystal structure of ethyl 6-(2-nitrophenyl)imidazo[2,1-b]thiazole-3-carboxylate, C14H11N3O4S
  37. Crystal structure of (4-(4-isopropylphenyl)-1H-pyrrol-3-yl)(ferrocenyl)methanone, C24H23FeNO
  38. Crystal structure of bis(methylammonium) tetrathiotungstate(VI), (CH3NH3)2[WS4]
  39. Crystal structure of 6,11-dihydro-12H-benzo[e]indeno[1,2-b]oxepin-12-one, C17H12O2
  40. Crystal structure of 3-[(4-phenylpiperidin-1-yl)methyl]-5-(thiophen-2-yl)-2,3-dihydro-1,3,4- oxadiazole-2-thione, C18H19N3OS2
  41. Crystal structure of N-isopropyl-1,8-naphthalimide C15H13NO2
  42. TiNiSi-type EuPdBi
  43. Crystal structure of 1-(p-tolylphenyl)-4-(2-thienoyl)-3-methyl-1H-pyrazol-5-ol, C16H14N2O2S
  44. The crystal structure of 3-(3-carboxypropyl)-2-nitro-1H-pyrrole 1-oxide, C7H9N3O5
  45. The crystal structure of tetraaqua-bis(2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetato-k2O:N)-tetrakis(2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetato-k1N)trizinc(II) hexahydrate C36H52N18O32Zn3
  46. The crystal structure of 4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium 4-hydroxy-3,5-dimethoxybenzoate monohydrate, C25H30FN3O9
  47. Crystal structure of bis(DL-1-carboxy-2-(1H-indol-3-yl)ethan-1-aminium) oxalate — acetic acid (1/2)
  48. Crystal structure of methyl (E)-4-((4-methylphenyl)sulfonamido)but-2-enoate, C12H15NO4S
  49. The crystal structure of actarit, C10H11NO3
  50. The crystal structure of bicyclol, C19H18O9
  51. The crystal structure of topiroxostat, C13H8N6
  52. Crystal structure of 2,2-dichloro-N-methyl-N-(4-p-tolylthiazol-2-yl)acetamide, C13H12Cl2N2OS
  53. Crystal structure of 4-(trifluoromethyl)-7-coumarinyl trifluoromethanesulfonate C11H4F6O5S
  54. Crystal structure of (1,4,7,10,13,16-hexaoxacyclooctadecane-κ6O6)-((Z)-N,N′-bis(2-(dimethylamino)phenyl)carbamimidato-κ1N)potassium(I)
  55. Crystal structure of (Z)-2-(5-((4-(dimethylamino)naphthalen-1-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, C18H16N2O3S2
  56. Crystal structure of (4-fluorobenzyl)triphenylphosphonium bromide, C25H21BrFP
  57. The crystal structure of dichlorido-[6-(pyridin-2-yl)phenanthridine-κ2N, N′]zinc(II)-chloroform (1/1), C19H13N2ZnCl5
  58. Crystal structure of (E)-(3-(2,4-dichlorophenyl)acryloyl)ferrocene, C19H14Cl2FeO
  59. The crystal structure of (E)-7-chloro-1-cyclopropyl-6-fluoro-3-((2-hydroxybenzylidene)amino)quinolin-4(1H)-one, C19H14ClFN2O2
  60. Crystal structure of 2-bromo-11-(((fluoromethyl)sulfonyl)methyl)-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide, C16H13BrFNO4S2
  61. Crystal structure of 2-chloro-11-(((fluoromethyl)sulfonyl)methyl)-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide, C16H13ClFNO4S2
  62. Crystal structure of 5-(2,2-difluoropropyl)-5-methyl-6-oxo-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline-3-carbonitrile, C20H15F2N3O
Downloaded on 14.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2025-0092/html?srsltid=AfmBOorv30SmhV5XfIjc1_dKJ0lrXApLcpHtRPAla_e3dwrm4vhL_5TR
Scroll to top button